Get startedLog in
    Picture of Spago Nanomedical AB (publ) logo

    SPAGO — Spago Nanomedical AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapSucker Stock
    All News

    Brief: Spago Selects Cmed As CRO For Clinical Trial With Tumorad

    Picture of Spago Nanomedical AB (publ) logoSpago Nanomedical AB (publ)
    10/11/2021 07:09
    Nov 10 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.ST :
    * SPAGO NANOMEDICAL SELECTS CMED AS ITS CRO FOR THE FIRST
CLINICAL
TRIAL WITH TUMORAD®
    * HAS SIGNED AN AGREEMENT WITH GLOBAL CRO CMED GROUP LIMITED
FOR
DEVELOPMENT OF FIRST CLINICAL STUDY WITH COMPANY'S THERAPY
PROJECT TUMORAD

Source text for Eikon:  ID:nMFNc1rllf 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))

    Recent news on Spago Nanomedical AB (publ)

    See all news